8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Feb 3, 2010)

Filed February 3, 2010For Securities:PFE

Summary

Pfizer Inc. (PFE) filed this Form 8-K on February 3, 2010, to report its financial results for the fourth quarter of 2009. The primary purpose of this filing is to incorporate by reference the press release issued on the same day, which contains detailed financial information. Investors should refer to the press release (Exhibit 99) for specific performance metrics, revenue figures, earnings per share, and any forward-looking statements or guidance provided by the company. This filing serves as the official mechanism for disseminating these important quarterly results to the public and the market. While the 8-K itself is brief and primarily procedural, the attached press release is the substantive content for investors. It would detail the company's performance in the crucial fourth quarter of 2009, including key financial indicators and any strategic updates or outlook. Investors should carefully review this press release to understand the company's financial health, operational performance, and its implications for future growth and profitability.

Key Highlights

  • 1Pfizer Inc. (PFE) announced its fourth quarter 2009 financial results via a press release filed on February 3, 2010.
  • 2The 8-K filing incorporates the full press release (Exhibit 99) by reference, which contains the detailed financial information.
  • 3Investors are directed to the press release for specific details on fourth-quarter operations and financial condition.
  • 4This filing is primarily a procedural update to officially disseminate the company's quarterly earnings announcement.
  • 5The event date for the financial results was February 2, 2010.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Pfizer Inc.'s financial results for the fourth quarter of 2009 by incorporating the press release announcing these results.

The detailed financial results are contained within the press release issued by Pfizer on February 3, 2010, which is included as Exhibit 99 to this 8-K filing and is incorporated by reference.

Investors should look for key financial metrics such as revenue, net income, earnings per share (EPS), and any forward-looking statements, guidance, or commentary on the company's performance and outlook for the upcoming periods.

This specific 8-K filing primarily focuses on the dissemination of financial results. While the press release (Exhibit 99) may contain some discussion of operational performance, any significant new strategic updates would typically be announced separately or detailed within the press release if they directly impacted the reported financial results.